Investment
Features
FeesSafety
Academy
More
Pluang+

Regeneron's melanoma trial fails, stock drops over 10%, investors urged to explore legal options.

Market News
18 May 2026
PRNewsWire
View Source
Bearish
pluang ai news

Regeneron Pharmaceuticals announced that its Phase 3 melanoma trial combining fianlimab and Libtayo did not meet the primary endpoint against Keytruda, causing the stock to fall more than 10%. Prior optimism from company executives about the trial's progress led to significant investor losses. Legal firm Levi & Korsinsky is investigating whether Regeneron made misleading statements about the trial's potential and is encouraging affected investors to review their rights and consider participating in a securities investigation. No immediate action is required to remain eligible for potential recovery claims.

More News (REGN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App